Petosemtamab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Petosemtamab (MCLA 158) 是一种抗EGFR (Kd: 0.22 nM) 和抗 LGR5 (Kd: 0.86 nM) 单克隆抗体 (mAb)。Petosemtamab 导致 LGR5+ 癌细胞中的 EGFR 信号传导阻断和受体降解。Petosemtamab 可用于头颈部鳞状细胞癌 (HNSCC)、转移性结直肠癌 (CRC) 等实体瘤的研究。

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC).

Western Blot Analysis Cell Line:P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids Concentration:1 μg/mL Incubation Time:1, 6, 24, 72 h Result:Time-dependently degraded EGFR.

Animal Model:Esophageal squamous, gastric adenocarcinoma and head & neck PDX models Dosage:25 mg/kg/week Administration:Intravenous injection (i.v.) for 6 weeks.Result:Inhibited tumor growth.

——

Angiogenesis

EGFR

EGFR

——

——

2213450-26-9

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years